Locations:
May 13, 2021/Neurosciences/Epilepsy

Epilepsy Care in Older Adults: New Insights Into Seizure Types and RNS Response

Two studies add to understanding of little-understood patient populations

brain scan epilepsy

Generalized epilepsy is surprisingly not uncommon among elderly patients with epilepsy, and older adults with drug-resistant epilepsy who cannot undergo surgery can safely be treated with responsive neurostimulation therapy (RNS). These two findings from separate Cleveland Clinic research investigations were presented at the recent 2021 American Academy of Neurology virtual annual meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The elderly is the fastest-growing population in this country, but most of what we know about epilepsy comes from managing children and younger adults,” says Cleveland Clinic epileptologist Vineet Punia, MD, MS, senior author of the two studies. “This research revealed some surprising findings and provides important information related to diagnosis and management in older and elderly patients.”

Characterizing generalized epilepsy in elderly patients

New-onset generalized epilepsy is most commonly seen in children, adolescents and young adults, in whom its clinical characteristics and management have been well described. Much less is known about its occurrence in the elderly, and generalized epilepsy has traditionally been thought to rarely develop as a new-onset seizure disorder in this age group.

This single-center cohort study offers the largest patient set of its type in the literature, with 30 patients at least 60 years old (mean age, 67.6; 63% female) who were admitted to a Cleveland Clinic epilepsy monitoring unit (EMU) and diagnosed with EEG-confirmed generalized epilepsy.

EMU evaluation was indicated to diagnose or characterize spells in 17 patients (56.7%) and to assess seizure burden in 13 others (43.3%). Key findings were as follows:

  • The mean age at epilepsy onset was 16 years (interquartile range, 6-56).
  • Ten patients (33.3%) had late-onset epilepsy (after age 50).
  • Four patients (13.3%) had never been on anti-seizure medications.
  • Twenty patients (66.6%) had medication-refractory epilepsy.
  • Generalized tonic-clonic seizures were experienced by 19 of 20 patients (95%) who had initial seizure onset age before age 50 compared with six of 10 patients (60%) who had initial onset at or beyond age 50 (P = 0.03).

Advertisement

“We were surprised to find that a substantial proportion of elderly patients with generalized epilepsy developed it as an older adult,” says Dr. Punia. “It shows that we should not be too quick to always assume late-onset epilepsy is focal, and that further evaluation should be considered when indicated.”

Dr. Punia adds that his group is further studying generalized epilepsy in older and elderly patients outside of the EMU setting.

Assessing RNS therapy in older patients

RNS has proven to be a safe and effective treatment for drug-resistant epilepsy in patients who cannot undergo surgery. However, RNS has not been specifically studied in older patients; investigations reported in the literature are with patients at an average age of about 35.

This retrospective study involved 57 patients treated at Cleveland Clinic with RNS for at least six months, including:

  • Twelve patients age 50 or older (21%), with a mean age at implantation of 54.9 years
  • Forty-five patients younger than 50 (79%), with a mean age at implantation of 30.2 years

The cohorts had significant differences at baseline: the older group had more comorbidities (P < 0.01) and a longer duration of epilepsy (P < 0.01).

Results were as follows:

  • Seizure reduction of at least 50% was achieved in eight patients (67%) in the older cohort versus 23 (51%) in the younger cohort.
  • Freedom from seizures was achieved in three patients (25%) in the older cohort versus five (11%) in the younger cohort.
  • RNS-related complications occurred in zero patients in the older cohort compared with four patients in the younger cohort (P < 0.001).
  • Whereas the mean number of daily anti-epilepsy medications decreased following RNS therapy in the older cohort (from 2.73 to 2.36), it increased following RNS therapy in the younger cohort (from 2.84 to 3.07).

Advertisement

“Our findings show that RNS is a feasible and safe therapy for older patients with drug-resistant epilepsy who cannot undergo epilepsy surgery,” concludes Dr. Punia. “Outcomes in older patients compared favorably with those in younger patients despite the fact that the older patients tended to have longer duration of epilepsy.”

Continuing research in older adults and elderly patients

Dr. Punia notes that continued research in these age groups is important, as one should not assume that conclusions from studies on younger patients are universally applicable or that older and elderly patients have “grown accustomed to” their disorder and would not benefit from therapy changes. His group recently found that quality-of-life gains from epilepsy surgery reaped by older patients are similar to those in their younger counterparts.

Dr. Punia’s team is currently investigating how best to manage medications in older and elderly patients. “Some of these patients have been on the same medications for 50 years or more, and it’s worth taking a look at whether the medications are optimally effective with minimal side effects,” he adds.

Advertisement

Related Articles

illustration of street entrance to a hospital emergency area

Architecture as a Therapeutic Tool: Acute Stroke Care in Our New Neurological Building

A rare opportunity to design for speed, care coordination, recovery and continuous monitoring

Doctor and hospital tech standing next to an older patient in a hospital bed

Inpatient Program Reduced Medication Errors in Patients With Parkinson’s Disease

Multidisciplinary, proactive approach also improved discharge outcomes

floating CAR T cell against background of other cells

Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650&#215;450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

illustration of a bright clinical room with clinicians inside

Inside Our Neurological Institute’s Next-Generation Advanced Therapeutics Space

Combining customized care, research capabilities and flexibility for the future

stylized illustration of human brain made up of cogs and wheels
October 9, 2026/Neurosciences/Brain Health

How Alzheimer’s Disease Studies Need to Evolve in the Targeted Therapy Era

Leading investigators outline a new roadmap for clinical trials and observational research

Ad